Kornimate/medical-research-clean huggingface dataset:
an intervention trial for cardiac neuropathy in type 1 diabetes

Conditions: Diabetic Autonomic Neuropathy

Summary: the focus of this project is cardiovascular diabetic autonomic neuropathy (dan). dan affects the nerves that control heart rate and blood flow to the heart in people with diabetes. dan may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart. three medications will be tested for their effectiveness in dan.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * a1c \<9% * mild neuropathy * mild retinopathy * mild nephropathy exclusion criteria: * history of drug or alcohol dependence, heart disease, viral illness, liver disease, advanced kidney disease * pregnant or nursing * severely overweight

Keywords: type 1 diabetes oxidative stress diabetic complications neuropathy
rate of total joint infection 90-day after surgery following irrigation with next science no-rinse solution vs soc alone

Conditions: Joint Infection

Summary: a prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of next science no-rinse solution (hereby referred to as ns) vs soc (saline irrigation). the next science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than soc (saline) arm


Eligibility criteria:
inclusion criteria: 1. adult that meets at least one of the below criteria at time of screening: * american society of anesthesiologists (asa) 3 2 * bmi \>35 * patient with functional limitations as a result of disease1: * poorly treated hypertension * poorly treated diabetes * chronic renal failure * bronchospastic disease * disease with intermittent exacerbations * stable angina * implanted pacemaker * known history as an active nicotine use (smoker) * known history of uncontrolled diabetes mellitus (hgba1c \> 7.0) * known history of end stage organ disease * known history of inflammatory arthritis and currently on rheumatological medication (dmards) * known history of current active cancer treatment (chemotherapy) * venous disease (surgical risk calculator from acs-nsqip) * charleston comorbidity score \> 2 * elixhauser score \>11 * age 65 or older 2. subject is scheduled to primary joint replacement. 3. subject is willing and able to comply with all study procedures including transportation to the study site for all scheduled visits and be available for the duration of the study. 4. subject has understood, signed, and dated the informed consent form. exclusion criteria: 1. unable to provide signed and dated informed consent. 2. unable or unwilling to comply with all study-related procedures. 3. known history of allergic reaction to any of the study products or its components, including any products used for standard of care (such as dressings or any coverings) 4. subject has contraindications to general anesthesia 5. any subject positive for covid-19 virus at time of surgical screening 6. subjects have evidence of prolonged qt segment, per ekg. 7. subjects from a vulnerable population, in accordance with 45 cfr 46 subparts b, c, and d
botulinum toxin type a for neuropathic pain in patients with diabetic peripheral polyneuropathy

Conditions: Neuralgia

Summary: the purpose of this study is to determine whether botulinum toxin a is effective in the treatment of neuropathic pain in patients with diabetic peripheral polyneuropathy.


Eligibility criteria:
inclusion criteria: * • more than twenty years of age * patients should have 4 or more items positive among the 10 items of the dn4 questionnaire. * persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months * a pain score of 4 or more on the numeric rating scale exclusion criteria: * • neuropathic pain caused by confounding factors other than diabetic neuropathic pain * contraindicated for botulinum toxin type a * a change in pain medication one month prior to study enrollment * a condition involving neuromuscular junction (ex. eaton lambert disease, myasthenia gravis) * person who received botulinum toxin type a within three months prior to study enrollment
weight loss effect of akkermansia muciniphila in obese patients

Conditions: 28≤BMI≤35Kg/m2

Summary: this study intends to study the effect of akkermansia muciniphila on weight loss and the improvement of blood inflammation and metabolic indexes in obese patients with low body mass index (bmi) through multi-center clinical studies, and for the first time to innovatively explore the weight loss mechanism of akkermansia muciniphila by comparing the changes in brain function and fecal microbiota before and after intervention.


Eligibility criteria:
inclusion criteria: - 1) age 18-65 years old; 2）28≤bmi≤35kg/m2； 3) willing and able to comply with the protocol during the study period, and be able to cooperate with the completion of various examinations during the trial. written informed consent is provided prior to entry into study screening, and the patient has understood that the study can be withdrawn at any time from the study without any loss exclusion criteria: 1. pregnant or lactating women, in the reproductive period and not taking contraceptive measures; 2. oral antibiotics in the past 1 month prior to enrollment; 3. no use of probiotic prebiotic products before 3 weeks of intervention; 4. people without a fitness fat loss program or history of gastric surgery during the intervention period; 5. patients with severe gastrointestinal diseases; 6. those who are known to be allergic to synbiotics or similar products; 7. patients with no self-awareness and those with mental abnormalities; 8. have a history of organ transplantation or malignant tumor disease; 9. concurrent use of other experimental drugs or in other clinical trials; 10. have a history of alcohol, tobacco and other drug abuse; 11. those who are expected to be unable to complete the magnetic resonance examination; 12. combined with serious medical diseases or conditions: such as clinically serious (i.e., active) cardiac disease, severe, uncontrolled medical diseases and infections, severe uncontrollable digestive disorders, severe electrolyte disorders, active disseminated intravascular coagulation, major organ failure, such as decompensated heart, pulmonary, hepatic, renal failure, peripheral neuropathy symptoms, etc.
relationship between computer and cancer

Conditions: Thyroid Cancer

Summary: thyroid cancer is one of the most common malignant carcinomas. the incidence of thyroid cancer has risen in the past years. the recrudesce rate is highly raised. computer is widely used by people nowadays, is it a predisposing factor to the highly raised recrudesce rate? this research observed two random assigned groups, in which the patients were diagnosed by pathologic results. one group were strictly prohibit with using computer, the other were not told. finally collect the recrudesce rate of each group, analyze the data by statistic software.


Eligibility criteria:
inclusion criteria: * thyroid cancer exclusion criteria: * non-thyroid cancer
topical sirolimus for the treatment of pachyonychia congenita (pc)

Conditions: Pachyonychia Congenita

Summary: a study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with pc. subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. for certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. blood levels will test systemic absorption of sirolimus. other safety and efficacy measures will be taken through the 39-week study duration. funding source - fda oopd


Eligibility criteria:
inclusion criteria: subjects must: * be capable of understanding the purpose and risks of the study and sign a written informed consent form (icf) * be male or female ≥ 16 years of age at the time of the screening visit * have a confirmed diagnosis of pc by genotyping (e.g., familial) and clinically correlated painful keratoderma. * have roughly symmetrical calluses of similar severity on the plantar surface of both feet * women of childbearing potential must have a negative serum pregnancy test * subjects, whether male or female, with reproductive potential and who are sexually active must agree to use double-barrier contraception methods exclusion criteria: a subject with any of the following criteria is not eligible for inclusion in this study: * use of other investigational drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a biopsy) * significant condition in the dermatologic treatment area such as trauma, or nonhealing chronic wound * pregnant or nursing (lactating) female, or a positive serum pregnancy test * active infection either systemic or local near the site of treatment requiring chronic or prolonged use of antimicrobial agents * known immunodeficiency including: hepatitis a; hepatitis b; hepatitis c; human immunodeficiency virus (hiv) prior and current treatment * unable to be discontinued from drugs known to either be inducers or inhibitors of cyp3a4/5 enzymes * unable to be discontinued from drugs known to be p-glycoprotein inhibitors

Keywords: pachyonychia congenita
techniques to enhance patient comfort in sedation-risk free colonoscopy

Conditions: Screening of Colonic Polyps

Summary: hypotheses 1. loading the sigmoid colon with warm water and warm water irrigation for dealing with spasm (study treatment) will significantly reduce the proportion of patients complaining of abdominal discomfort compared with no water loading and waiting for spasms to subside (control treatment). the median discomfort score reported by the patients will be significantly lower in the group receiving the study treatment than the group receiving control treatment. hypothesis 2. exploratory hypothesis: there are differences in secondary outcome variables when patients managed by the study and control treatments are compared. co-variables affect the primary and secondary outcome variables.

the purpose of the study is to conduct a rct study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy. the specific aim is to compare study treatment of warm water loading and irrigation when spasms occur with control treatment of no water loading and waiting for spasms to subside. the proportion of patients complaining of abdominal discomfort and their discomfort score are the primary outcome variables. the secondary outcome variables and co-variables described below will be recorded in a prospective manner to ensure completeness of data collection. in preliminary clinical observation at va sepulveda acc, 25 to 30% of va patients accept colonoscopy without sedation. the goal of this study is to find ways of further reducing discomfort associated with unsedated colonoscopy.

Eligibility criteria:
inclusion criteria: * accepts adult healthy male and female patients * at least 18 years of age * in need of colonoscopy for screening or follow up of colonic polyps * willing to consent and be randomized exclusion criteria: * patients receiving outpatient narcotic treatment * patients who report excessive anxiety * patients with moderate to severe abdominal discomfort * unable to provide consent * have poor bowel preparation

Keywords: colonoscopy polyps
femtosecond laser arcuate keratotomy versus toric intraocular lens implantation in cataract surgery

Conditions: Cataract; Astigmatism

Summary: in modern cataract surgery, residual astigmatism continues to be one of the major factors influencing patients' visual quality and satisfaction. the goal of this study is to compare the clinical outcomes of femtosecond laser arcuate keratotomy in one eye and toric intraocular lens implantation in the contralateral eye for astigmatism correction in patients undergoing femtosecond laser-assisted cataract surgery. the study is a prospective randomized comparative study. patients with binocular regular corneal astigmatism ranging from 0.75 to 3.00 d will be recruited. the patient will randomly receive femtosecond laser arcuate keratotomy in one eye and receive toric intraocular lens implantation in the contralateral eye. long term evaluation will be performed to compare the visual acuity, subjective manifest refraction, and corneal topography between groups.


Eligibility criteria:
inclusion criteria: * cataract patients * patients with binocular regular corneal astigmatism ranging from 0.75 to 3.00 d * patients who plan to receive femtosecond laser-assisted cataract surgery exclusion criteria: * patients with ocular surface abnormalities such as irregular corneal astigmatism, corneal scarring, keratoconus, and pterygium) * patients with history of ocular trauma or surgery * patients with coexisting ocular disorders such as glaucoma, retinal vascular occlusive disease, retinal detachment, diabetic retinopathy, and any optic nerve-related pathologies * patients with concurrent severe systemic diseases * patients who lack of cooperation

Keywords: astigmatism correction femtosecond laser arcuate keratotomy toric intraocular lens implantation femtosecond laser-assisted cataract surgery
influence of suture type on emergency midline laparotomy closure

Conditions: Linea Alba Hernia; Evisceration; Operation Wound; Suture; Complications, Mechanical

Summary: there is no clear recommendation in international guidelines regarding the type of suture to be used for closing emergency midline laparotomies. it is recommended to follow the same principles as in elective surgery, thus performing the closure with a continuous suture of slowly absorbable monofilament 2-0 with small-bites technique. currently, there are several slowly absorbable sutures available on the market, and our center uses two: pds® and monomax®. these two sutures are currently used interchangeably at our institution based on the preferences of each surgeon. objective: study whether there are differences between these two sutures in the closure of emergency midline laparotomy.


Eligibility criteria:
inclusion criteria: * \>18 years old, patients undergoing emergency midline laparotomy by the general surgery department. exclusion criteria: * \<18 years old, previous midline laparotomy
effects of an ict-platform for assessment and management of patient-reported symptoms during treatment for breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the effects of an interactive information and communication technologies (ict) -platform for use in a smartphone or tablet in patients treated with neoadjuvant chemotherapy for breast cancer. the hypothesis is that clinical management will be improved and costs reduced and safe and participatory care promoted, when patients report symptoms in an application which provides self-care advice and instant access to professionals.


Eligibility criteria:
inclusion criteria: * the diagnosis of breast cancer * patients who will receive neoadjuvant chemotherapy * literacy in the swedish language exclusion criteria: * patients who need an interpreter at the doctor's visit * patients who have a known severe cognitive impairment

Keywords: breast cancer cytostatic agents nursing health literacy quality of life oncology nursing self care symptom management participatory care person-centered care information and communication technology patient-reported symptoms mobile device
early oral supplementation in improving nutritional status in patients undergoing hematopoietic stem cell transplant

Conditions: Malignant Neoplasm

Summary: this clinical trial studies the use of early oral supplementation in improving nutritional status in participants undergoing hematopoietic stem cell transplant. impaired nutritional status in participants undergoing hematopoietic stem cell transplant has been linked to decreased outcomes such as increased length of hospital stay and increased time to engraftment (an important milestone in transplant recovery). early oral supplementation may increase nutritional status and help to promote a positive outcome in participants undergoing transplant.

primary objectives: i. to determine if early oral supplementation improves nutritional status, decreases length of hospital stay, and shortens time to engraftment of hematopoietic stem cell transplant (hsct) participants. secondary objectives: i. serum albumin, serum 25-hydroxy vitamin d, and the degree of mucositis, as scored by the national cancer institute's common toxicity criteria (nci-ctc), a validated and widely accepted scale used for rating mucositis. the purpose of our secondary aims is to observe a potential correlation between the retrospective and prospective groups, as well as assess the need for future research based on these correlations. outline: participants receive boost plus orally (po) twice daily (bid) or pro-stat 101 po bid beginning one week before scheduled hsct and continuing until hospital discharge. if participants do not tolerate the boost plus or pro-stat, they receive a milkshake po once daily (qd) as an alternative.

Eligibility criteria:
inclusion criteria: * undergoing an autologous or reduced intensity conditioning (ric) allogeneic hsct * a serum albumin greater than or equal to 2.5 g/dl * able to understand and sign consent exclusion criteria: * patients who have malabsorption problems, such as ulcerative colitis, irritable bowel syndrome, crohn's disease, bowel surgery such as gastric bypass, and celiac disease
comparative clinical evaluation of daily disposable lenses in symptomatic lens wearers

Conditions: Myopia

Summary: the purpose of this trial is to evaluate the extent to which symptoms improve in symptomatic contact lens wearers when fit with one of 5 different daily disposable contact lenses.


Eligibility criteria:
inclusion criteria: * currently wear spherical, soft contact lenses replaced at intervals of 2 weeks or monthly. * habitually wear lenses for at least 8 hours per day, 4 days per week, for at least the past 6 months. * report 2 or more qualifying symptoms with current contact lenses with a frequency of "frequently" or "all the time" * able to achieve va of at least 20/40 in each eye with habitual correction and with study lenses at dispense. * other protocol inclusion/exclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks immediately prior to enrollment. * currently enrolled in any clinical trial. * any use of medications for which contact lens wear could be contraindicated as determined by the investigator. * history of corneal refractive surgery. * cylinder correction greater than 1.00 d. * current monovision contact lens wearers. * other protocol inclusion/exclusion criteria may apply.
circulation improving resuscitation care (circ)

Conditions: Cardiac Arrest; Cardiopulmonary Resuscitation

Summary: during resuscitation of out of hospital cardiac arrest patients the use of a mechanical chest compression device autopulse will improve survival compared to manual compressions.

sudden out-of-hospital cardiac arrest (ooh-ca) remains a significant cause of death, in spite of recent declines in overall mortality from cardiovascular disease. several studies document sub optimal quality of manual chest compressions and this may influence outcome. however, studies comparing manual and mechanical chest compressions have resulted in conflicted results. the investigators think this may be based on methodology and design issues of the trials as much as not focusing on training and experience in operating a mechanical device clinically. therefore the investigators will focus on these issues and implement three phases in the study (in field training, run in phase, and study phase). the investigators will also focus on early use of mechanical cpr after arrival at patient side and randomization at arrival. in order to achieve this the investigators will follow the norwegian cpr guidelines with 3 min cpr before defibrillation and the 3 min algorithm. quality of cpr will be monitored.

Eligibility criteria:
inclusion criteria: * patents aged 18 years (or local age of consent) or more who suffer non-traumatic arrest of presumed cardiac etiology in an out-of-hospital setting and who do not meet any of the exclusion criteria below. exclusion criteria: * traumatic arrest (blunt, penetrating, burns) * arrest due to exsanguinations, strangulation, smoke inhalation, drug overdose, electrocution, hanging, drowning. * known or clinically apparent pregnancy * do not attempt to resuscitate (dnar) orders * apparent patient weight more than 225 kg (500 lbs) * wards of the state * prisoner * cpr device other than autopulse * patients who are reached after 16 minutes after the time of emergency call (911). this exclusion is determined at the time of crf abstraction, not during treatment of the patient. * if patient is unaccompanied, or accompanied by a person or persons unfamiliar with their his-tory, determination of these exclusion criteria will, perforce, be left to the best estimation of the rescue personnel. at no time, should an attempt to determine these criteria be allowed to delay the administration of life-saving treatment. * these criteria will be determined in the best estimation of the rescue personnel, or if the autopulse signals that the patient is outside the parameters for autopulse deployment.

Keywords: cpr mechanical manual outcome survival quality
focal prostate radio-frequency ablation

Conditions: Prostate Cancer

Summary: the main purpose of this study is to evaluate the safety and efficacy of focal (targeted) radio-frequency ablation (rfa) in men with low or intermediate-risk, clinically localized prostate cancer.


Eligibility criteria:
inclusion criteria: * men 18 years of age or older * diagnosis of adenocarcinoma of the prostate, confirmed by h.l. moffitt cancer center review * no prior treatment for prostate cancer * eastern cooperative oncology group (ecog) performance status of 0 or1 * prostate cancer clinical stage t2a and below * psa \<10 ng/ml (this will be the prostatic specific antigen (psa) level prompting the initial prostate biopsy) * prostate size \<60 cc on transrectal ultrasound * pre-enrollment biopsy parameters (as per h.l. moffitt c.c. review): minimum of 10 biopsy cores; gleason score 6 aor 7; unilateral cancer (only right-sided or left-sided, not bilateral). exclusion criteria: * men less than 18 years of age * medically unfit for anesthesia * histology other than adenocarcinoma * biopsy does not meet inclusion criteria * men who have received any hormonal manipulation (antiandrogens; luteinizing hormone releasing hormone (lhrh) agonist; 5-alpha-reductase inhibitors) within the previous 6 months

Keywords: adenocarcinoma prostate encage™ focal bipolar radiofrequency ablation radiofrequency ablation (rfa) radiotherapy